Lumida
/ADCT
⌘K
ADC Therapeutics SA

ADC Therapeutics SA

ADCT
$0.97USD-3.16%-0.03 today

MARKET CAP

123.2M

P/E (TTM)

FWD P/E

DAY RANGE

$1 – $1

52W RANGE

$1
$5

AI Summary

Stalk
Buy NowMedium

ADCT has formed an early post-capitulation base in Stage 1 with clear exhaustion after a deep washout. The chart is extreme oversold, and RSI is recovering from lows. Price is tightly holding above the rising 9EMA and 21EMA, confirming support. Mean‐reversion rules in Stage 1 mandate a medium‐term bullish bias and open a buy‐now opportunity at short‐term EMA support.

  • Q1 net product revenues rose 15% YoY to $20M, indicating stable demand for Zynlanta.
  • $231M cash runway supports trials and operations through 2028, reducing dilution risk.
  • Q1 net loss narrowed to $33M vs $38.6M YoY but still indicates negative profitability.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2019FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$2.3M$209.9M$69.6M$70.8M$81.4M
YoY %+8870.4%-66.9%+1.8%+14.9%
P / Sales1.3x2.0x2.7x5.5x
EV / Sales1.7x5.2x6.6x8.6x
Gross Profit, Adj.$2.3M$206.6M$67.0M$64.9M$75.6M
YoY %+8729.4%-67.6%-3.2%+16.4%
Margin %100.0%98.4%96.4%91.6%92.9%
EV / Gross Profit1.8x5.4x7.2x9.2x
EBITDA, Adj.$-117.8M$-121.0M$-164.8M$-129.3M$-107.7M
YoY %-2.7%-36.2%+21.5%+16.7%
Margin %-5032.2%-57.6%-236.9%-182.6%-132.3%
EV / EBITDA-3.0x-2.2x-3.6x-6.5x
EBIT$-119.4M$-123.3M$-166.0M$-130.7M$-121.5M
YoY %-3.3%-34.6%+21.3%+7.0%
Margin %-5102.5%-58.8%-238.6%-184.4%-149.3%
EV / EBIT-3.0x-2.2x-3.6x-5.7x
Net Income$-116.5M$-157.1M$-240.1M$-157.8M$-142.6M
YoY %-34.9%-52.8%+34.2%+9.6%
Net Margin-4977.9%-74.9%-345.1%-222.8%-175.3%
EPS (GAAP)-$2.64-$2.01-$2.94-$1.62-$1.12
YoY %+23.9%-46.3%+44.9%+30.9%